NovMetaPharma Co., Ltd.
KONEX-listed biotech developing NovDB2, NovDKD, and NovFSHD drug pipelines for metabolic disease and fibrosis.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KONEX in 2015, NovMetaPharma develops drugs for metabolic, inflammatory, and fibrotic diseases. Its pipeline centers on diabetes drug NovDB2, kidney drug NovDKD, and FSHD drug NovFSHD, plus health food sales and C01 skin booster marketing. It targets Phase 2 before out-licensing, with Phase 2b done for NovDB2/NovOB and IRB approval for NovDKD's Phase 2 trial.
Products & technology
- 신약 관련 원료
- 건강기능식품
- C01 기반 스킨부스터
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 2 1)
- Phase 2Cyclo-Z2023-03-14
14 trial sites
R&D and key agreements
Source: DART corporate disclosureNovDB2 · 2형 당뇨병 · 미국 임상 2b상 완료 · Novel-mechanism insulin resistance drug; follow-up trial integrated into the NovDKD Phase 2 program
NovDKD · 당뇨병콩팥병 · 국내 임상 2상(2024년 2분기 IRB 승인 완료) · Novel-substance kidney disease drug; safety verified through FDA Phase 2b in type 2 diabetes patients
NovFSHD / NovFSHD2 · FSHD(안면견갑상완근위축증) · 2026년 중 임상 2상 진입 예정(일반인 대상 1상 완료) · Efficacy verified in animal models by a major North American FSHD institution
NovOB-M · GLP1 비만치료제 관련 근감소증 · 1상 완료(일반인 대상) · Studied as a co-administered therapy with GLP-1 obesity drugs to address muscle loss/function decline
NovFS-IP · 특발성 폐섬유증 · 1상 완료(일반인 대상) · FDA orphan drug designation granted; safety verified through FDA Phase 2b in type 2 diabetes patients
NovSR · 근감소증(노화 관련) · 1상 진입 예정(IND 안전성 자료 확보)
NovDMD · 듀센근이영양증 · 1상 예정(IND 안전성 자료 완료) · Related research published in Advanced Science (2024)
NovAP · 급성췌장염 · 전임상 · Novel-mechanism drug; seeking a partner for out-licensing/co-development
NovLC · 간암 · 전임상 · Shown potential to overcome sorafenib resistance; seeking an out-licensing partner
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition